Physician profile
Neda Heidari
NPI 1003028556
$8,432.08
in general payments reported to CMS, 2019-2025
45 companies · $2,594 in 2025
The $2,594 reported for 2025 was more than what 85% of Behavioral Neurology & Neuropsychiatry providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $789 · 2020: $270 · 2021: $617 · 2022: $851 · 2023: $1,412 · 2024: $1,900 · 2025: $2,594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,902 · Education: $3.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,901.66 |
| Education | $3.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,882.13 | 2019-2025 | |
| Pfizer INC. | $886.45 | 2019-2025 | |
| Biogen, INC. | $665.17 | 2019-2025 | Vumerity, Tysabri |
| Acadia Pharmaceuticals INC | $401.46 | 2019-2025 | Nuplazid |
| Ucb, INC. | $390.82 | 2019-2025 | Rystiggo, Briviact, Nayzilam |
| Allergan, INC. | $330.70 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $278.72 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $229.04 | 2022 | |
| Neurelis, INC. | $189.19 | 2023-2025 | Valtoco |
| Lundbeck LLC | $177.21 | 2019-2025 | Vyepti |
| Eisai INC. | $167.65 | 2024-2025 | |
| Biohaven Pharmaceuticals, INC. | $167.42 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $161.37 | 2025 | Hyqvia |
| Lilly USA, LLC | $158.74 | 2019-2025 | Kisunla, Emgality |
| Sk Life Science, INC. | $139.23 | 2025 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neda Heidari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.